Impact Factor 3.915 | CiteScore 3.7
More on impact ›
The Cardio-Oncology section of Frontiers in Cardiovascular Medicine is to provide a prime publication platform for this emerging field in medicine. It should speak to clinicians and researchers across the multiple diciplines that contribute to this field, including cardiology, oncology, hematology, radiation oncology, surgery, internal medicine, pediatrics, palliative care and geriatrics. It is a primary intent of this section to cultivate communication across these disciplines and along the scopes of clinical, basic and translational sciences.
The Cardio-Oncology section of Frontiers in Cardiovascular Medicine welcomes original articles, reviews, perspectives, case reports and other article types to choose from. Furthermore, this section welcomes clinical trial updates, including initial observations made in phase I and II cancer trials, and articles on the design of clinical trials in cardio-oncology. The Cardio-Oncology section also provides coverage of key meetings relevant to the field as well as a fellows corner and practice updates, including practice consensus and guideline documents. State-of-the-art reviews are accepted but will also be commissioned as will be viewpoints and debates (pros and cons topics). Certain topics may be highlighted in thematic collections (Research Topics).
The Cardio-Oncology section of Frontiers in Cardiovascular Medicine will cover the full and broad scope of cardio-oncology. The topics of interest include cardiovascular toxicities of cancer therapeutics including cardiomyopathy, heart failure, coronary artery disease, valvular heart disease, arrhythmias and device management, hypertension and renal disease, radiation-induced cardiovascular disease and side effects, multimodality imaging and biomarker use in cancer patients, genomics, proteomics, and metabolomics research in cardio-oncology, clinical trials in cardio-oncology, cardiovascular observations in cancer trials, including phase I and II trials on new cancer therapeutics, preclinial disease models, basic science and mechanisms of cardiovascular toxicities and their prevention.
Cardio-oncologists have to walk a thin line between harm and benefits of cancer treatments. Our goal is to provide a forum that covers the entire emerging interface between cardiovascular medicine and oncology and to inspire and inform the readers to stay most current and engaged in the field of cardio-oncology.
Indexed in: PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE), Google Scholar, DOAJ, CrossRef, Semantic Scholar, Ulrich's Periodicals Directory, CLOCKSS
PMCID: all published articles receive a PMCID
Cardio-Oncology welcomes submissions of the following article types: Addendum, Brief Research Report, Case Report, Clinical Trial, Correction, Curriculum, Instruction, and Pedagogy, Editorial, General Commentary, Hypothesis and Theory, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Review, Specialty Grand Challenge and Systematic Review.
All manuscripts must be submitted directly to the section Cardio-Oncology, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact cardiovascularmedicine.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact cardiovascularmedicine@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org